Investor Presentaiton slide image

Investor Presentaiton

Our Journey: Three decades of delivering on promises Formative years with focus on APIs Global footprint, Established dominance in Core APIs + PFIs, Entered Finished dosages space Expanding into complex generics + Strengthening market penetration in regulated markets Moving towards complex technology 1984 1990 1991 1993 1995 2001 2002 2003 2005 2008 2010 2013 2014 2014 2015 2016 2019 2020 2022 2022 Established first PFI facility at Jeedimetla Incorporated Granules India Private Limited Opened 2nd API facility in Jeedimetla Granules formed as Triton Labs to produce Paracetamol API at Bonthapally Listed on the BSE Entered the Finished dosage segment Merger of Triton with Granules New Paracetamol plant at Bonthapally Listed on the Hyderabad Stock Exchange Set up a large-volume PFI facility in Gagillapur and a wholly owned subsidiary Granules USA for marketing in the US Received USFDA Acquired API manufacturing facility in Vizag to further strengthen the API portfolio Established 15,000 sqft R&D facility in Hyderabad approval for its first ANDA Laid down the foundation for its Oncology OSD Plant in Vizag Entered OTC business in US through Granules Consumer Healthcare Incorporated Granules Pharmaceutical Inc in the US to focus on formulations in the US Acquired Sajjla Bio Labs to augment Biotechnology R&D Laid foundation for the largest single manufacturing site for MUPS facility Commenced sale of Rx Products in the US under the GPI Label Completed share buy-back worth Rs.311 Cr (including taxes and transaction cost) 9
View entire presentation